MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
191.37
-13.16
-6.43%
Pre Market: 194.06 +2.69 +1.41% 04:00 05/15 EDT
OPEN
200.25
PREV CLOSE
204.53
HIGH
205.00
LOW
189.49
VOLUME
16
TURNOVER
176.53M
52 WEEK HIGH
205.97
52 WEEK LOW
119.18
MARKET CAP
28.25B
P/E (TTM)
20.54
1D
5D
1M
3M
1Y
5Y
1D
BIOGEN <BIIB.O>: PIPER SANDLER RAISES TARGET PRICE TO $225 FROM $214
Reuters · 5h ago
Biogen Inc. Stock Sheds 6.4%, Underperforms Peers
Dow Jones · 12h ago
Biogen Inc. stock underperforms Thursday when compared to competitors
MarketWatch · 12h ago
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
TipRanks · 13h ago
Best Healthcare Stocks to Buy in 2026
The Motley Fool · 13h ago
Biogen Moves Alzheimer's Drug to Late-Stage Trials. Wall Street Thinks It's a Mistake.
Barron‘s · 14h ago
Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
TipRanks · 14h ago
BUZZ-U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras
Reuters · 14h ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.